Marino Stram & Associates’s GSK GSK Stock Holding History

Marino Stram & Associates’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$344K	Buy	6,560 +85	+1%	+$4.5K	0.05%	150
2026 Q1	$357K	Buy	6,475 +78	+1%	+$4.23K	0.06%	140
2025 Q4	$314K	Buy	6,397 +1	+0%	+$47	0.06%	149
2025 Q3	$276K	Buy	6,396 +188	+3%	+$7.34K	0.05%	158
2025 Q2	$238K	Buy	6,208 +39	+0.6%	+$1.49K	0.05%	161
2025 Q1	$239K	Buy	6,169 +42	+0.7%	+$1.54K	0.05%	149
2024 Q4	$207K	Buy	6,127 +30	+0.5%	+$1.08K	0.05%	164
2024 Q3	$249K	Buy	6,097 +36	+0.6%	+$1.47K	0.06%	150
2024 Q2	$233K	Buy	6,061 +1,056	+21%	+$44.4K	0.06%	150
2024 Q1	$215K	Buy	+5,005	New	+$206K	0.05%	164
2019 Q2	–	Sell	-160	Closed	-$8K	–	279
2019 Q1	$8K	Hold	160	–	–	0.01%	322
2018 Q4	$8K	Hold	160	–	–	0.01%	299
2018 Q3	$8K	Hold	160	–	–	0.01%	319
2018 Q2	$8K	Sell	160 -24	-13%	-$1.21K	0.01%	316
2018 Q1	$9K	Hold	184	–	–	0.01%	317
2017 Q4	$8K	Buy	+184	New	+$8.5K	0.01%	329

Other funds holding GSK

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Marino Stram & Associates's GSK Position: Q2 2026 in Review

Marino Stram & Associates increased its GSK (GSK) stake by 1.3% in Q2 2026, buying an estimated $4.5K and bringing the position to 6,560 shares worth $344K. The position accounts for 0.05% of the portfolio, ranked #150.

Marino Stram & Associates first reported a position in GSK in Q4 2017 and has held it in 16 quarters since. The position peaked at $357K in Q1 2026. 1,040 funds tracked by Wall St. Rank hold GSK as of Q2 2026.

Marino Stram & Associates held 6,560 shares of GSK worth $344K as of Q2 2026.
Marino Stram & Associates bought 85 GSK shares in Q2 2026, an estimated $4.5K.
GSK made up 0.05% of Marino Stram & Associates's portfolio in Q2 2026, its #150 holding.
Marino Stram & Associates first reported a position in GSK in Q4 2017 and has held it in 16 quarters since.
Marino Stram & Associates's GSK position peaked at $357K in Q1 2026.
1,040 funds tracked by Wall St. Rank held GSK as of Q2 2026.

Based on Marino Stram & Associates's 13F filing for Q2 2026, filed 24 Jul 2026.